An K Phan, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 541 Main St Ste 400, South Weymouth, MA 02190 Phone: 781-952-1280 |
Sarah M Sciascia, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 541 Main St, Suite 301, South Weymouth, MA 02190 Phone: 781-952-1480 Fax: 781-952-1481 |
Mario L Dominguez, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1690 Main St, Suite 4, South Weymouth, MA 02190 Phone: 781-337-8688 Fax: 781-337-8754 |
Mary Catherine Gustilo, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 541 Main St, Suite 301, South Weymouth, MA 02190 Phone: 781-952-1480 Fax: 781-952-1481 |
Michael N Doupe, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 541 Main St, Suite 414, South Weymouth, MA 02190 Phone: 781-952-1433 Fax: 508-630-2462 |
Dr. Viduri Parekh, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 541 Main St, Suite 301, South Weymouth, MA 02190 Phone: 781-952-1480 Fax: 781-952-1481 |
Dr. Johvonne Michelle Claybourne, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 541 Main St 414, South Weymouth, MA 02190 Phone: 781-952-1433 |
News Archive
Leaky blood vessels that lose their ability to protect the spinal cord from toxins may play a role in the development of amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig's disease, according to research published in the April issue of Nature Neuroscience.
A new study by Massachusetts General Hospital investigators released today in JAMA Network Open, a publication of the Journal of the American Medical Association, showed that labeling food choices in a hospital cafeteria with simple "traffic-light" symbols indicating their relative health value was associated with a reduction in calories purchased by employees, and that the dietary changes were sustained over two years.
In an innovation critical to improved DNA sequencing, a markedly slower transmission of DNA through nanopores has been achieved by a team led by Sandia National Laboratories researchers.Solid-state nanopores sculpted from silicon dioxide are generally straight, tiny tunnels more than a thousand times smaller than the diameter of a human hair. They are used as sensors to detect and characterize DNA, RNA and proteins. But these materials shoot through such holes so rapidly that sequencing the DNA passing through them, for example, is a problem.
Two subset analyses from the landmark HORIZONS-AMI trial show that the anticoagulant bivalirudin lowers major bleeding and cardiac death versus the combination of heparin and a GP IIb/IIIa inhibitor in patients with ST-segment myocardial infarction (STEMI) who have disease of the left anterior descending artery (LAD), while in STEMI patients at highest risk for death, bivalirudin also confers the greatest mortality benefit.
Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.
› Verified 2 days ago